Investigating idiopathic pulmonary fibrosis in Greece (INDULGE IPF)

Study identification

• EU PAS number:
  EUPAS17015
• Study ID:
  44737
• Official title and acronym:
  Investigating idiopathic pulmonary fibrosis in Greece (INDULGE IPF)
• DARWIN EU® study:
  No
• Study countries:
  Greece
• Study description:
  To gain further insight on the characteristics, management, disease progression and the outcomes of patients with IPF, as diagnosed and treated under real-world, clinical practice conditions in Greece. More specifically, this registry will be used to: Provide a comprehensive clinical picture of IPF, Track access to health care and cost of caring for IPF patients over time, Examine the implementation of treatment guidelines used on patients diagnosed with IPF, according to the existing diagnosis guidelines, Characterization of patients on different treatments. To provide information regarding survival and mortality causes, IPF exacerbations as well as IPF patient co-morbidities including myocardial infarction, CNS infarction, other arterial thromboembolic events, deep vein thrombosis, hemorrhage, gastrointestinal perforation and pulmonary hypertension. Data regarding IPF patient hospitalization will be collected and evaluated with regards to potential respiratory causes, and there will be documentation of treatment patterns and economic aspects. Patients will be followed up for 2 years and information regarding IPF treatment changes since the last visit will be collected.
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Planned:16/01/2017

Actual:17/02/2017

Study start date

Planned:31/03/2017

Actual:04/04/2017

Date of final study report

Planned:30/05/2022

Actual:29/03/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Ellas S.A.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable